Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma

Cancer Research

Volumn 61, Issue 24, 2001, Pages 8617-8623

  Zha, Shan ^a   Sauvageot, Jurga ^a   Ewing, Charles M ^a   Faith, Dennis A ^a   Nelson, William G ^a   Isaacs, William B ^a   Gage, Wesley R ^a   Saria, Elizabeth A ^a   Putzi, Mathew J ^a   De Marzo, Angelo M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ATROPHY; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DISEASE PROGRESSION; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035893745     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Cyclooxygenases: Structural, cellular, and molecular biology
2. New insights into the role of COX 2 in inflammation
3. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer
4. Molecular pathology of cyclooxygenase-2 in neoplasia
5. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
6. Expression of cyclooxygenase-2 in human lung carcinoma
7. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
8. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin
9. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder
10. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
11. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
12. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors
13. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
14. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate
15. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts
16. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment
17. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression
18. Expression of cyclooxygenase-2 in prostate carcinoma
19. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
20. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
21. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
22. Inverse association of prostate cancer and nonsteroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study
23. Immunohistochemical expression of cyclooxygenase (COX)-2 in colorectal adenomas
24. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
25. Mutagenesis and carcinogenesis: Endogenous and exogenous factors
26. Blocking the endogenous formation of N-nitroso compounds and related carcinogens
27. Prostate pathology, histology and molecular perspectives
28. Histology and cellular kinetics of prostatic atrophy
29. Atrophy and hyperplasia in the prostate proper
30. Atrophy and regeneration in the pathogenesis of prostatic carcinoma
31. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis
32. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia
33. Postatrophic hyperplasia of the prostate gland: Neoplastic precursor or innocent bystander?
34. GSTAI expression in normal, pre-neoplastic, and neoplastic human prostate tissue
35. Rapid microwave-stimulated fixation of entire prostatectomy specimens
36. Tissue microarrays for high-throughput molecular profiling of tumor specimens
37. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: The prostate specialized program of research excellence model
38. Accessory sex gland function in normal young (20-25 years) and middle- aged (50-55 years) men
39. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern-blot analyses, in situ hybridization and immunohistochemical stairings with monoclonal and bispecific antibodies
40. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue
41. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer
42. Alteration in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma
43. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
44. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
45. Role of BAX in the apoptotic response to anticancer agents
46. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
47. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis
48. DNA oxidation induced by cyclooxygenase-2
49. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer